ATMP Sweden omdelade detta
🚀 Advancing personalized tissue therapies: VERIGRAFT P-TEV clinical trial update 🚀 We are excited to share progress from our ongoing Phase I/II clinical trial in Europe! Eleven of the planned fifteen patients have now been treated with our Personalized Tissue-Engineered Vein (P-TEV) product, and four of these patients have completed the twelve-month follow-up period. Our trial aims to evaluate P-TEV’s potential to cure chronic venous insufficiency, a condition caused by faulty valves that fail to prevent venous blood backflow. Primary endpoints focus on safety, assessing risks such as infection, mechanical failure, and thrombosis. Secondary endpoints will measure treatment efficacy. “So far, the results are exceeding expectations, confirming safety and showing significant promise for our innovative approach,” said Petter Björquist, CEO of VERIGRAFT. “Our commitment to advancing regenerative medicine and providing personalized treatments that enhance recovery and improve quality of life is yielding encouraging outcomes." 🔗 Click the link in the comments section below to learn more about VERIGRAFT’s innovative tissue therapy technology 👇 #RegenerativeMedicine #ClinicalTrials #HealthInnovation #PersonalizedTherapies #PrecisionMedicine #ChronicVenousInsufficiency #PTEV #Gothenburg #Sweden #VERIGRAFT SwedenBIO CCRM Nordic Business Region Göteborg AB ATMP Sweden SwedenBIO Business Sweden